文献速递临床试验与 GCP流行病学与生物统计

在肯尼亚测试不同模式的药房启动与管理HIV暴露前和暴露后预防:集群随机对照试验方案

Testing different models of pharmacy-based HIV pre- and post-exposure prophylaxis initiation and management in Kenya: protocol for a cluster-randomized controlled trial.
PubMed 文献 · Trials · 2025-12-30

该方案在肯尼亚中部和西部60家药房开展四臂集群随机对照试验,比较客户自付、实施方付费、实施方付费加咨询员支持三种药房启动与管理HIV暴露前预防(PrEP)和暴露后预防(PEP)模式与转诊至诊所的标准模式。主要结局为入组后60天客户报告的PrEP启动和持续(任何续药),次要结局包括PEP启动、PEP转PrEP、重复PEP使用及60天和270天的PrEP/PEP启动与持续。试验旨在为利用私营药房提供PrEP/PEP及推广政策提供证据。

要点

  • 60家药房按1:1:1:1随机分为客户自付、实施方付费、实施方付费加咨询员支持、转诊对照四臂。
  • 主要结局为入组后60天客户报告的PrEP启动和持续(任何续药)。
  • 次要结局包括PEP启动、PEP转PrEP、重复PEP使用及60天和270天的PrEP/PEP启动与持续。

核心结论

  • 该试验将生成关于利用私营药房提供PrEP和PEP的潜在益处以及客户、实施方和/或HIV检测服务(HTS)咨询员支持下的药房提供相对有效性的证据,研究结果可能为推广提供政策依据和参考方法。

研究设计与样本

  • Pharm PrEP集群随机对照试验在肯尼亚中部和西部60家药房开展,四臂按1:1:1:1随机分组,首次入组日期为2023年6月26日。
  • 合格药房需政府许可、有私人房间并愿意完成研究活动(包括3天提供者培训)。

主要发现

  • 尚未报告试验结果,方案仅描述主要结局为入组后60天客户报告的PrEP启动和持续(任何续药)。
  • 次要结局包括PEP启动、PEP转PrEP、重复PEP使用、PrEP/PEP启动以及入组后60天和270天的PrEP/PEP持续。
  • 将评估实施结局(如可接受性、可行性、成本),从客户和提供者角度进行。

关键数值与推荐

  • 客户自付模式:客户每次PrEP/PEP就诊向药房支付250肯尼亚先令(约2美元)。
  • 实施方付费模式:客户不付费,实施方每次PrEP/PEP就诊向药房支付250肯尼亚先令。
  • 实施方付费加咨询员支持模式:客户不付费,由HTS咨询员支持提供,实施方每次PrEP/PEP就诊向药房支付100肯尼亚先令(约1美元)。
  • 转诊对照模式:客户不付费,实施方每次转诊至诊所PrEP/PEP向药房支付100肯尼亚先令。
  • 提供PrEP/PEP的药房从政府库存免费获得支持性商品。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In Kenya, as in many African countries, private pharmacies are ubiquitous, frequently accessed, and underutilized for the delivery of HIV prevention services. Whether enabling private pharmacies to initiate and manage clients on HIV pre- and post-exposure prophylaxis (PrEP and PEP) leads to greater uptake and continuation than the current standard-pharmacy referral to clinic-based PrEP/PEP-is unknown. To address this gap and inform how private pharmacies might partner with the public sector, we are testing several models of pharmacy-delivered PrEP/PEP in comparison to the current standard. METHODS: The Pharm PrEP cRCT is a 60-pharmacy, four-arm cluster-randomized controlled trial ongoing in Central and Western Kenya (first enrollment: 26 June 2023). Eligible pharmacies were licensed by the government, had a private room, and were willing to complete research activities (including a 3-day provider training). Study pharmacies were randomized 1:1:1:1 to (1) client-sustained delivery, in which clients pay pharmacies 250 KES (~$2 USD) per PrEP/PEP visit; (2) implementor-sustained delivery, in which clients pay nothing and implementors pay pharmacies 250 KES per PrEP/PEP visit; (3) implementor-sustained + counselor-supported delivery, in which clients pay nothing, delivery is supported by an HIV testing services (HTS) counselor, and implementors pay pharmacies 100 KES (~$1 USD) per PrEP/PEP visit; or 4) referral (control), in which clients pay nothing and implementors pay pharmacies 100 KES per referral to clinic-based PrEP/PEP. Pharmacies delivering PrEP/PEP receive supporting commodities free from government stock. Primary outcomes are PrEP initiation and continuation (any refilling) reported by clients 60 days post-enrollment; secondary outcomes include PEP initiation, PEP-to-PrEP transition, repeat PEP use, PrEP/PEP initiation, and PrEP/PEP continuation at 60 and 270 days post-enrollment. Primary analyses will compare each intervention arm to the control; secondary analyses will compare intervention arms to one another. We will additionally assess implementation outcomes (e.g., acceptability, feasibility, cost) from client and provider perspectives. DISCUSSION: This trial will generate evidence on the potential benefits of leveraging private pharmacies for delivery of PrEP and PEP and the relative effectiveness of pharmacy delivery when subsidized by clients, implementors, and/or supported by HTS counselors. The findings may inform enabling policy and approaches for scale-up. TRIAL REGISTRATION: ClinicalTrials.gov NCT05842122. Registered on April 5, 2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Kareithi T, Roche SD, Meisner A, et al. Testing different models of pharmacy-based HIV pre- and post-exposure prophylaxis initiation and management in Kenya: protocol for a cluster-randomized controlled trial. Trials. 2025. PMID: 41466427. doi:10.1186/s13063-025-09384-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。